Pycnogenol, an antioxidant plant extract from the bark of the French maritime pine tree, has been shown to alleviate the symptoms of osteoarthritis in a study published in the December issue of the journal Redox Report. In the 55-patient analysis, as well as improving OA and pain, the agent significantly lowered plasma levels of the inflammatory marker C-reactive protein.
Results showed that Pycnogenol, which is owned by Guernsey firm Horphag Research, significantly lowered CRP from average 3.9mg/L at baseline to 1.1mg/L, reflecting essentially healthy levels. In the placebo group, a marginally lower CRP level was detected. Other blood parameters indicative of acute inflammation likewise decreased with Pycnogenol, such as fibrinogen (lowered 37.1 %) and reactive oxygen species (down 29.9 %).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze